resTORbio Announces Initiation Of Phase 3 Clinical Program Of RTB101 In Clinically Symptomatic Respiratory Illness – Clinical Leader

resTORbio Announces Initiation Of Phase 3 Clinical Program Of RTB101 In Clinically Symptomatic Respiratory Illness – Clinical Leader
resTORbio Announces Initiation Of Phase 3 Clinical Program Of RTB101 In Clinically Symptomatic Respiratory Illness  Clinical LeaderresTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small ... read more
Source: Google NewsPublished on 2019-05-10